Mr Barry Clare

KANDO id: 33560

Bio

Created Boots Healthcare International, the international 'over the counter' consumer healthcare business, of the Boots Company plc. Starting with sales of £100 million (80% UK), the business became the fastest growing OTC company in Europe, with sales in 2001 of £460 million and profits of £70 million. BHI was sold to Reckitt Benckiser for £1.93 billion. Major international brand successes included Nurofen, Strepsils and Clearasil, managed through leading-edge business processes keeping the organisation lean and enhancing profitability. As a member of the Group Board, was also involved in the strategic initiatives in the core UK Boots the Chemists retail chain, as well as the ground-breaking approach to pension funds. Non-executive director of Standard Chartered Bank from 2000 to 2003, and brought to the Group his experience in international marketing, retailing and acquisition integration, as the Bank increased its focus on the consumer business in emerging markets. Became Vice President, Marketing for the speciality chemical company, Diversey in Toronto then owned by the Canadian brewer, Molson, and later acquired by Unilever. Following the success of BHI, joined the Group Main Board at Boots. Re-organised the international health and beauty retail division, stemming losses and implementing a low-cost new business model, which facilitated faster, easier new market introductions in Hong Kong and Taiwan. Natural science graduate from Cambridge.

Education